SCHEMBL10147437

SCHEMBL10147437

CCOC(=O)c1nc(-c2ccc(C)cc2C)no1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.58
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
RAB9A P51151 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
S1PR1 P21453 6/20 0.41
S1PR3 Q99500 3/20 0.41
ALPL P05186 1/20 0.40
SLC26A6 Q9BXS9 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
S1PR5 Q9H228 3/20 0.40
MAPK1 P28482 2/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233714 0.81 HTT (0.71) HTTMAPTLMNAKDM4ENPSR1
SCHEMBL28816278 0.80 HTT (0.56) HTTMAPTLMNAKDM4ENPSR1
SCHEMBL29775781 0.80 HTT (0.56) HTTMAPTLMNASMN1; SMN2RAB9A
SCHEMBL2566003 0.80 HTT (0.56) HTTMAPTLMNASMN1; SMN2RAB9A
SCHEMBL15465704 0.78 HTT (0.54) HTTMAPTLMNASMN1; SMN2NPC1
SCHEMBL10147450 0.77 CA1 (0.52) MAPTLMNAKDM4ENPSR1SMN1; SMN2
SCHEMBL5607278 0.77 HTT (0.54) HTTMAPTLMNAKDM4ENPSR1
SCHEMBL10147416 0.76 ALDH1A1 (0.53) MAPTLMNAKDM4ENPSR1SMN1; SMN2
SCHEMBL31591590 0.76 HTT (0.64) HTTMAPTLMNASMN1; SMN2MEN1
SCHEMBL31591599 0.75 HTT (0.71) HTTMAPTLMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P HTT 26/4885MAPT 84/4885LMNA 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.